Citations

Clear

1676 citation(s) found for "Saß, Christian".

Validation of plasma biomarker immunoassay‐based models for predicting brain amyloid positivity in cognitively impaired individuals
Syrjanen, Jeremy A. , Figdore, Daniel J. , Griswold, Michael , Wiste, Heather J. , Dierkhising, Ross , Kremers, Walter K. , Lachner, Christian , Graff‐Radford, Neill R. , Day, Gregory S. , Graff‐Radford, Jonathan , Jack, Clifford R. , Knopman, David S. , Petersen, Ronald C. , Bornhorst, Joshua , Algeciras‐Schimnich, Alicia , Initiative, for the Alzheimer’s Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | November 5, 2026 | Volume: 22 | Issue: 11 | Pages: No page available

10.1002/alz.71946 | PMID 42982748 Get It

Abstract INTRODUCTION Combining Alzheimer's disease blood biomarkers may improve prediction of amyloid positivity (A+) compared with single biomarkers. METHODS Logistic regression models using plasma phosphorylated tau 217 (p‐tau217), amyloid beta (Aβ) 42, and Aβ40 were developed in cognitively impaired (CI) participants from Mayo Clinic Rochester (MCR) and validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) and Mayo Clinic Florida (MCF) cohorts. Performance was measured by area under the curve (AUC) and Probability of Amyloid Positivity Score (PAPS). RESULTS Plasma p‐tau217 alone showed high AUC (95% confidence intervals) across cohorts MCR, 0.928 (0.900–0.953); ADNI, 0.938 (0.915–0.959); MCF, 0.935 (0.893–0.970). Adding Aβ42 to regression models yielded marginal model improvement MCR, 0.940 (0.915–0.963); ADNI, 0.945 (0.922–0.965); MCF, 0.960 (0.925–0.986). Utilization of two cutpoints (≥ 90% sensitivity and specificity), yielded ≤ 10% intermediate results for p‐tau217, and ≤ 8% for p‐tau217+Aβ42. Addition of Aβ40 did not improve models’ performance. DISCUSSION An immunoassay‐based p‐tau217 PAPS model accurately predicted amyloid positivity across independent CI cohorts and achieved confirmatory‐test performance with two cutpoints. The added value of Aβ42 was modest and cohort dependent, supporting the potential of use of p‐tau217–based PAPS in clinical workflows.
Recent Advances in Lipid Nanoparticles for Cancer Vaccines: From Antigen Delivery to Personalized Immunotherapy
Rachamala, Hari Krishnareddy , Singh Angom, Ramcharan , Marepally, Srujan

Mayo Clinic

International Journal of Molecular Sciences | October 12, 2026 | Volume: 27 | Issue: 20 | Pages: 9023

10.3390/ijms27209023 | PMID 42941797 Get It

In recent years, lipid nanoparticles (LNPs) have shown great promise as highly flexible delivery systems for cancer vaccines, which enable effective cargo delivery and allow for controlling their distribution, cell-targeting ability and immunogenicity. Innovations in ionizable lipid chemistry, biodegradable formulations, RNA engineering and LNP design resulted in improvements in RNA encapsulation, endosomal escape, delivery outside the liver, and targeting of lymphoid organs and antigen-presenting cells. All these achievements led to an expansion of strategies for developing cancer vaccines from using only mRNA to personal neoantigen vaccines, self-amplifying RNA (saRNA), circular RNA (circRNA), peptide/protein vaccines, and multi-purpose platforms that combine antigen delivery and modulation of the immune system. LNPs are also studied as tools for altering the tumor microenvironment (TME) and boosting anti-tumor immunity through local delivery of cytokines and innate immune modulators. Preliminary clinical results with personalized mRNA neoantigen vaccines show strong potential for this approach. However, inflammatory toxicity, suitability for repeated dosing, off-target delivery, difficulties with large-scale production, formulation stability, personalized production schedule and regulatory issues are still significant challenges. New biodegradable and PEG-free formulations, innovations in manufacturing and lyophilization technology, and AI-based approaches in lipid screening could help overcome some of these problems.
Multimorbidity, Polypharmacy, and Neighborhood Disadvantage as Determinants of Cognitive Performance in the ARCHES Cohort
Gebremichael, Dagem , Bekena, Semere , Singh, Ramkrishna K. , Walker, Alexis I. B., Millsap, Mario , Banks, Christian F., Bekele, Bisrat, Zhu, Yiqi, Trani, Jean-Francois, Babulal, Ganesh M.

Mayo Clinic

Journal of Applied Gerontology | October 7, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/07334648261491344 | PMID 42842789 Get It

Background African American adults experience a disproportionate burden of dementia, shaped by structural and clinical factors that remain unclear. Objective To quantify associations between multimorbidity, polypharmacy, and cognition in the context of neighborhood disadvantage. Methods This study is a cross-sectional analysis of 348 African American adults aged 45–92 years (mean 64.3 years; 73.6% female) from the Aging Research Characterizing Health Exposome via Social drivers (ARCHES) cohort. Comorbidity burden was assessed using a modified Charlson Comorbidity Index (CCI), polypharmacy as ≥5 medications, and neighborhood disadvantage using the Area Deprivation Index (ADI). Linear regression estimated associations with a Preclinical Alzheimer’s Cognitive Composite (PACC). The polypharmacy model included modified CCI as a covariate, and effect modification by ADI was assessed using an interaction term between polypharmacy and ADI. Results Higher modified CCI was associated with lower cognitive performance (B = −0.071; 95% CI: −0.130, −0.012). Polypharmacy was not independently associated with cognition after modified CCI adjustment (B = −0.081; β = −0.057; p = 0.257). No significant ADI interaction was found (p = 0.064).
Clinical Factors Associated With Discordant Plasma P-Tau217 and Established Alzheimer Disease Biomarkers
Shir, Dror , Algeciras-Schimnich, Alicia , Piura, Yoav D , Bornhorst, Joshua , Figdore, Daniel J , Lachner, Christian , Graff-Radford, Neill R , Day, Gregory S

Mayo Clinic

Neurology | October 1, 2026 | Volume: 107 | Issue: 8 | Pages: No page available

10.1212/wnl.0000000000218591 | PMID 42821845 Get It

Neighborhood Contemporary Redlining and Racial Mortgage Lending Bias and Cardiovascular Outcomes in Women With Breast Cancer
Llanos, Adana A. M. , Beyer, Kirsten M. M. , Powell‐Wiley, Tiffany M. , Mujahid, Mahasin S. , Choudhury, Tanisha , Sutton, Arnethea L. , Brown‐Podgorski, Brittany L. , Bikomeye, Jean C. , Hong, Hyokyoung G. , Lawrence, Wayne R , Llanos, Adana A M , Beyer, Kirsten M M , Powell-Wiley, Tiffany M , Mujahid, Mahasin S , Choudhury, Tanisha , Sutton, Arnethea L , Brown-Podgorski, Brittany L , Harris, Alexandra R , Bikomeye, Jean C , Ewing, Aldenise P , Hong, Hyokyoung G , Doose, Michelle , Brewer, LaPrincess C , Abnet, Christian C , Magnani, Jared W , Lawrence, Wayne R. , Brewer, LaPrincess C. , Abnet, Christian C. , Magnani, Jared W.

Mayo Clinic

Journal of the American Heart Association | September 9, 2026 | Volume: 15 | Issue: 18 | Pages: No page available

10.1161/jaha.125.049367 | PMID 42714450 Get It

Background Studies have demonstrated neighborhood structural inequities are associated with cardiovascular outcomes among breast cancer survivors. We investigated the associations between bias in mortgage lending practices (contemporary redlining and racial lending bias) and cardiovascular outcomes in women with breast cancer. Methods Using the SEER (Surveillance, Epidemiology, and End Results)–Medicare database, we identified 51 007 Black and White women diagnosed with breast cancer between 2010 and 2014 with follow‐up through 2020. We used Home Mortgage Disclosure Act data to calculate census‐tract contemporary redlining index and racial lending bias index, and assessed indices continuously and categorically (low, moderate, or high). We used Cox proportional hazards regression to estimate multivariable‐adjusted, cause‐specific hazard ratios (HRs) for major adverse cardiovascular events, ischemic heart disease, heart failure, stroke, and cardiovascular death. Results In the overall population, a 10%‐unit increase in redlining was associated with increased risk of major adverse cardiovascular events (HR, 1.04 [95% CI, 1.02–1.06]). Among Black women, those in high redlining neighborhoods had an increased heart failure risk compared with those in low redlining neighborhoods (HR, 1.22 [95% CI, 1.05–1.41]). Similarly, White women in high redlining neighborhoods had an increased risk of ischemic heart disease (HR, 1.23 [95% CI, 1.15–1.30]) and stroke (HR, 1.09 [95% CI, 1.03–1.16]). Black women in high racial lending bias neighborhoods had reduced cardiovascular mortality risk compared with those in low racial lending bias neighborhoods (HR, 0.69 [95% CI, 0.54–0.90]). Conclusions We identified associations between contemporary redlining and cardiovascular outcomes among breast cancer survivors. High racial lending bias was associated with reduced cardiovascular mortality risk among Black women. Bias in mortgage lending practices may serve as a structural driver of cardiovascular disparities.
Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[ 18 F]FDG PET-Negative Marrow: Results From an International Retrospective Study
Just, Marissa, Collins, Natalie B. , Crane, Jacquelyn, Harrison, Douglas, Affinita, Maria C., Allen-Rhoades, Wendy, Alessi, Alessandra , Asaftei, Sebastian Dorin , Freitag, Martin T. , Iftner, Jessica L., Khalatbari, Hedieh, Luettichau, Irene von , Mauz‐Körholz, Christine , Rovera, Guido , Sims, Justin, Voss, Stephan D. , Birz, Suzi , Sparber‐Sauer, Monika , Linardic, Corinne M. , Network, for the INSTRuCT Imaging/Pathology/Biology, Baldari, Giorgio , Borrego-Dorado, I., Baffa, Nicodemo, Caldarella, Carmelo , Degitz, Carmen , DiGianvittorio, Michael, Fischer, Alexandra, Fox, Josef J. , Fuso, Giuseppe Arturo, Hiemcke-Jiwa, Laura, Heinzel, Alexander , Jacob, Sebastian, Kleinwechter, Martha, Kröning, Pia, Lohrmann, Christian, Morani, Ajaykumar C. , Nadel, Helen, Parisi, Marguerite T. , Perruccio, Katia , Pugliano, Martina, Font, C. Ramos , Cuomo, Maria Rosaria, Saab, Raya, Schäfer, Jürgen, Schachtrup, Kristina, Sternberg, Michele, Uhl, Markus, Verberne, Hein J., Nadel, Helen , Saab, Raya , Mercolini, Federico , Shulkin, Barry L , Collins, Natalie B , Alessi, Alessandra , Asaftei, Sebastian D , Arnold, Michael A , Chen, Sonja , FitzGerald, Forrest , Freitag, Martin T , de Keizer, Bart , Mauz-Koerholz, Christine , Rossig, Claudia , Rovera, Guido , Rutkowski, Stefan , Voss, Stephan D , Birz, Suzi , Bisogno, Gianni , Ebinger, Martin , Merks, Johannes H M , Sparber-Sauer, Monika , Haller, Bernhard , Weiss, Aaron R , Linardic, Corinne M , Schoot, Reineke A , Hettmer, Simone , Nadel, Helen , Just, Marissa A. , Shulkin, Barry L. , Affinita, Maria Carmen , Allen‐Rhoades, Wendy , Chen, Sonja , Chiaravalli, Stefano , Khalatbari, Hedieh K. , Keizer, Bart de , Yoshimi, Ayami , Bisogno, Gianni , Ebinger, Martin , Weiss, Aaron R. , Cheesman, Edmund , DiGianvittorio, Michael, Fanti, Stefano , Hiemcke‐Jiwa, Laura S. , Ruffini, Livia , Scarlattei, Maura , Verberne, Hein J. , Zucchetta, Pietro

Mayo Clinic

Journal of Clinical Oncology | August 24, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/jco-25-03080 | PMID 42636421 Get It

PURPOSE Detection of bone marrow disease has been a major component of rhabdomyosarcoma (RMS) staging with bilateral bone marrow aspirates/biopsies (BMAB) from the iliac crests considered the diagnostic gold standard. This study's goal was to determine if 2- 18 F-labeled fluorodeoxyglucose positron emission tomography/computed tomography ([ 18 F]FDG PET/CT) or PET/magnetic resonance imaging (MRI) may replace BMAB in RMS staging. METHODS Patients were recruited in Europe and North America. Medical records, FDG PET/CT or FDG PET/MRI (PET), and BMAB reports were collected retrospectively. Images were re-reviewed by nuclear medicine physicians at the patients' home institutions if PET reports indicated increased FDG uptake at bone/bone marrow sites or if tumor cells were detected in bone marrow samples. RESULTS PET imaging and BMAB were performed before chemotherapy and tumor resection in 301 patients with FDG-avid RMS. Bone marrow metastases were detected by PET and BMAB in 54, by PET only in 24, and by BMAB only in one of 301 patients with FDG-avid primary tumors. Absence of bone marrow metastases was confirmed by PET and BMAB in 222 of 301 patients. These observations translated into 98% sensitivity and 90% specificity for PET in detecting bone marrow metastases when BMAB was considered as gold standard. FDG-avid marrow disease was patchy (1-5 foci) in one third of cases. Patients with marrow disease indicated by PET and BMAB had more FDG-avid bone marrow foci, more metastatic sites, and lower survival than those with marrow disease indicated by PET only, suggesting more advanced disease stages. CONCLUSION Bone marrow sampling may be omitted in patients without evidence of FDG-avid bone marrow disease by PET. If there are FDG-avid bone marrow lesions, further investigation by MRI and/or biopsy should be considered.
Clinical Benefits Associated With Evinacumab in Pediatric Patients With Homozygous Familial Hypercholesterolemia
Reijman, M. D. , Kusters, D.M., Planken, R. Nils , Loewe, Christian , Verpalen, Victor A. , Hovingh, G. Kees , Neyer, Manuela, Draxler-Dworzak, Sophie, Mair, Katharina , Arbeiter, Klaus , Mueller‐Sacherer, Thomas, Groothoff, Jaap W. , Hutten, Barbara A. , Reijman, M D , Nigmann, Charlotte , Planken, R Nils , Loewe, Christian , Hovingh, G K , Neyer, Manuela , Draxler-Dworzak, Sophie , Mair, Katharina , Arbeiter, Klaus , Mueller-Sacherer, Thomas , Groothoff, Jaap W , Hutten, Barbara A , Greber-Platzer, Susanne , Wiegman, Albert , Kusters, D. Meeike

Mayo Clinic

Journal of the American Heart Association | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/jaha.125.048419 | PMID 42622232 Get It

Background Homozygous familial hypercholesterolemia (HoFH), characterized by extremely elevated low‐density lipoprotein cholesterol (LDL‐C) due to severely impaired LDL‐C clearance from circulation, remains challenging to treat. Here, we investigated clinical benefits of monoclonal antibody, evinacumab, inhibiting angiopoietin‐like 3, recently approved in children with homozygous familial hypercholesterolemia. Methods This retrospective, observational study included 13 children with homozygous familial hypercholesterolemia on oral lipid‐lowering therapy and assessed their attainment of LDL‐C goal, need for lipoprotein apheresis (LA), and cardiac plaque formation at initiation of evinacumab and at follow‐up of 2.0 (1.3–3.0) years. Results Evinacumab, initiated at age 11 (8.5–13.5) years, increased number of patients reaching LDL‐C goal from none before initiation to 9 of 13 (69%; P =0.004) at follow‐up. Mean±SD LDL‐C at follow‐up was 111 (44) mg/dL, compared with 206 (61) mg/dL before evinacumab (mean difference, −95 mg/dL [95% CI, −142 to −47]; P <0.001). Before initiation of evinacumab, 11 of 13 children received LA with average interval of 7.8 days. At follow‐up, LA frequency decreased in 7 of 11 children with average interval of 18.9 days; increase between LA sessions was 11.0 days (3.5–18.5; P =0.008), 42% longer session interval. For 3 (15%) children, due to evinacumab initiation, LA remained dispensable over the course of treatment. Coronary computed tomography angiography showed plaque stabilization (n=5), regression (n=3), and no formation (n=2), in 10 of 13 (77%) children, and plaque progression in 3 (23%) children. Conclusions Add‐on evinacumab increased number of children with homozygous familial hypercholesterolemia reaching and maintaining LDL‐C goal, concomitant reduction in LA frequency, and in most patients, stabilization or improvement in coronary computed tomography angiography findings.
Amyloid‐Related Imaging Abnormalities Summit Special Proceedings: Cardiovascular and Stroke Considerations for β‐Amyloid Immunotherapy in Alzheimer Disease
Greenberg, Steven M. , Iadecola, Costantino , Chou, Sherry , Cogswell, Petrice M, Elkind, Mitchell S.V. , II, William J. Hicks, Le, Caitlin, Levine, Deborah A. , Lipton, Richard B. , Massimo, Lauren, Mohl, Stephanie M. , Snyder, Heather M. , Yaffe, Kristine , Adams, Robert, Agronin, Marc, Atri, Alireza, Bauman, Mary Ann, Bernat, James L., Biffi, Alessandro , Blum, Sonja, Bussiere, Thierry, Carrillo, Maria C., Chiang, Gloria, Cato, Kenrick, Chaitoff, Alexander, Bakken, Suzanne, Schelke, Matthew W. , Cruz‐Flores, Salvador, Derdeyn, Colin, Dhand, Amar, Evans, David A., Gettel, Cameron, Goldstein, Larry B, Grill, Joshua, Kulshrestha, Ambar, Lam, Christine, Lazar, Ronald M. , Li, Hanlin , Madsen, Tracy, Ramanan, Vijay K., McCullough, Louise, Merino, José G., Orjuela, Karen, Guo, Michael, Messe, Steve, Tubiello, Maggie, Ruff, Christian T., Selim, Magdy, Sha, Sharon J., Sheth, Kevin, Stamm, Brian, Buckwalter, Marion, Skylar-Scott, Irina, Lavretsky, Helen, Saver, Jeffrey, Rabinovici, Gil D., VandeVrede, Lawren, Goyal, Manu S., Weisman, David C., Lipton, R.B. , Chou, Sherry H-Y , Seshadri, Sudha , Snyder, Heather M , Yaffe, Kristine , Zachrison, Kori S , Cogswell, Petrice M. , Hicks, William J., Massimo, Lauren , Seshadri, Sudha , Atri, Alireza, Blum, Sonja, Bussière, Thierry , Carlisle, Tara C. , Chaitoff, Alexander , Cruz-Flores, Salvador, Chyou, Janice Y. , Derdeyn, Colin P. , Gettel, Cameron J. , Goldstein, Larry B. , Grill, Joshua D. , Ishii, Makoto , Kulshreshtha, Ambar , Rabinstein, Alejandro A. , Ramanan, Vijay K. , McCullough, Louise D. , Merino, José G. , Messé, Steven R. , Ruff, Christian Thomas , Saklad, Stephen R. , Selim, Magdy H. , Shah, Sachin J. , Stamm, Brian , Buckwalter, Marion S. , Skylar-Scott, Irina A., Rabinovici, Gil D. , VandeVrede, Lawren , Chatterjee, Arindam R , Wunderink, Richard G.

Mayo Clinic

Journal of the American Heart Association | August 20, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1161/jaha.125.048108 | PMID 42622140 Get It

Background New antiamyloid therapies (AAT) for treating patients with early Alzheimer disease (AD) have become available in the past 3 years. Although AAT can be beneficial in slowing progression of AD, they also come with potentially serious side effects, particularly for patients requiring anticoagulation or thrombolysis for cardiovascular conditions. Given that most patients with AD are older and likely to have cardiovascular risk factors, there is urgent need for additional guidance for clinicians about potential risks and benefits associated with AAT for patients with cardiovascular comorbidities, best practices for management of these patients, and special considerations with respect to emergency evaluation and treatment of patients on AAT who develop acute neurological symptoms. Methods The American Heart Association convened 75 multidisciplinary experts for the Amyloid‐Related Imaging Abnormalities Summit: Cardiovascular and Stroke Considerations for β‐Amyloid Immunotherapy in AD in July 2025. These experts were divided into 8 work groups to evaluate the current evidence related to AAT usage in patients with cardiovascular risk factors and conditions and develop consensus‐based guidance for clinicians. Results This statement outlines the outcomes of the Summit, including considerations for prescribers, primary care professionals, emergency personnel, and health care system stakeholders. These considerations are intended to improve identification of patients as appropriate candidates for AAT, management of patients with co‐occurring AD and cardiovascular conditions, and their emergency evaluation and treatment. The statement also includes guidance for shared decision‐making, implementation of system changes for improving dementia care, and recommendations for future research and data collection to add to the body of evidence for treating patients with concomitant AD and cardiovascular conditions. Conclusions Building on lessons learned from the establishment of stroke systems of care, the consensus‐based considerations outlined in this document can serve as a foundation for AD systems of care aimed at ensuring optimal use of these ground‐breaking therapies.
Optimized plasma p‐tau217 and p‐tau217/Aβ42 cutoffs enhance detection of pre‐clinical Alzheimer's disease across diverse participants
Piura, Yoav , Aduen, Paula, Schecter, Leah, Jain, Manoj K, Algeciras‐Schimnich, Alicia, Petersen, Ronald C, Jr, Clifford R Jack, Graff‐Radford, Neill R, Lachner, Christian, Piura, Yoav D , Aduen, Paula A., Day, Gregory S , Jain, Manoj K, Algeciras‐Schimnich, Alicia , Figdore, Daniel J. , Bornhorst, Joshua , Petersen, Ronald C. , Jack, Clifford R. , Graff‐Radford, Neill R. , Lachner, Christian , Day, Gregory S.

Mayo Clinic

Alzheimer's & Dementia | August 20, 2026 | Volume: 22 | Issue: 8 | Pages: No page available

10.1002/alz.71763 | PMID 42619350 Get It

Abstract INTRODUCTION Plasma p‐tau217 and p‐tau217/Aβ42 reliably identify non‐Hispanic White individuals with symptomatic and pre‐clinical AD. However, performance across ethnoracially diverse groups remains unknown. METHODS Cognitively normal Black, Hispanic, and non‐Hispanic White participants completed cognitive evaluations, brain magnetic resonance imaging (MRI), amyloid and tau positron emission tomography (PET), and measures of kidney function. Plasma p‐tau217 and Aβ42 were measured using Fujirebio Lumipulse assays. Pre‐clinical AD detection was evaluated using symptomatic and cohort‐derived optimized cutoffs. RESULTS Among 191 participants (57 Black, 46 Hispanic White, 88 non‐Hispanic White), age‐adjusted plasma p‐tau217 and p‐tau217/Aβ42 performed similarly in detecting amyloid‐positive individuals (≥ 25 Centiloids), regardless of race/ethnicity. Both measures independently correlated with amyloid deposition, whereas estimated glomerular filtration rate (eGFR) correlated solely with p‐tau217. Pre‐clinical AD optimized cutoffs (p‐tau217 ≥ 0.132 pg/ml; p‐tau217/Aβ42 ≥ 0.0059) outperformed cutoffs established in symptomatic individuals (sensitivity: 83% vs. 57%; 77% vs. 63%; negative predictive value [NPV] > 93%). DISCUSSION Plasma biomarkers performed similarly across ethnoracially diverse cohorts. Optimized cutoffs may improve early detection and trial enrollment.